BR112013011600A8 - Derivados de pirazol aminopirimidina como moduladores de lrrk2 - Google Patents
Derivados de pirazol aminopirimidina como moduladores de lrrk2Info
- Publication number
- BR112013011600A8 BR112013011600A8 BR112013011600A BR112013011600A BR112013011600A8 BR 112013011600 A8 BR112013011600 A8 BR 112013011600A8 BR 112013011600 A BR112013011600 A BR 112013011600A BR 112013011600 A BR112013011600 A BR 112013011600A BR 112013011600 A8 BR112013011600 A8 BR 112013011600A8
- Authority
- BR
- Brazil
- Prior art keywords
- aminopyrimidine derivatives
- lrrk2
- compounds
- pyrazole
- modulators
- Prior art date
Links
- JOOFEGKZJOFZKJ-UHFFFAOYSA-N 1h-pyrazole;pyrimidin-2-amine Chemical class C=1C=NNC=1.NC1=NC=CC=N1 JOOFEGKZJOFZKJ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
derivados de pirazol aminopirimidina como moduladores de lrrk2. a presente invenção refere-se a compostos da fórmula i: ou sais farmaceuticamente aceitáveis dos mesmos, em que x, r^ 1^, r^ 2^, r^ 3^, r^ 4^, e r^ 5^ são como definidos aqui. da mesma forma descritos são os métodos de preparar os compostos e usar os compostos para tratamento de doenças associadas com receptor de lrrk2, tal como doença de parkinson.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41227310P | 2010-11-10 | 2010-11-10 | |
US61/412,273 | 2010-11-10 | ||
US201161546613P | 2011-10-13 | 2011-10-13 | |
US61/546,613 | 2011-10-13 | ||
PCT/EP2011/069696 WO2012062783A1 (en) | 2010-11-10 | 2011-11-09 | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112013011600A2 BR112013011600A2 (pt) | 2016-08-09 |
BR112013011600A8 true BR112013011600A8 (pt) | 2021-09-08 |
BR112013011600B1 BR112013011600B1 (pt) | 2022-01-11 |
Family
ID=44983512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013011600-5A BR112013011600B1 (pt) | 2010-11-10 | 2011-11-09 | Derivados de pirazol aminopirimidina, seu uso e composição que os compreende |
Country Status (28)
Country | Link |
---|---|
US (1) | US8815882B2 (pt) |
EP (3) | EP2638031B9 (pt) |
JP (3) | JP5986094B2 (pt) |
KR (1) | KR101566091B1 (pt) |
CN (1) | CN103313978B (pt) |
AR (1) | AR083813A1 (pt) |
AU (1) | AU2011328139A1 (pt) |
BR (1) | BR112013011600B1 (pt) |
CA (2) | CA3017869C (pt) |
CY (1) | CY1120073T1 (pt) |
DK (2) | DK2638031T3 (pt) |
EC (1) | ECSP13012611A (pt) |
ES (2) | ES2746134T3 (pt) |
HK (1) | HK1187605A1 (pt) |
HR (2) | HRP20172006T1 (pt) |
HU (2) | HUE046617T2 (pt) |
IL (1) | IL225234A0 (pt) |
LT (2) | LT3124483T (pt) |
MA (1) | MA34644B1 (pt) |
MX (1) | MX2013005199A (pt) |
NO (1) | NO2638031T3 (pt) |
PL (2) | PL3124483T3 (pt) |
PT (2) | PT2638031T (pt) |
RS (2) | RS56583B1 (pt) |
SG (1) | SG189043A1 (pt) |
SI (2) | SI2638031T1 (pt) |
TW (1) | TW201302733A (pt) |
WO (1) | WO2012062783A1 (pt) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2017140639A (ru) | 2011-05-23 | 2019-02-12 | Элан Фармасьютикалз, Инк. | Ингибиторы активности киназы lrrk2 |
LT2785711T (lt) * | 2011-11-29 | 2016-10-25 | F.Hoffmann-La Roche Ag | 2-(fenil arba pirid-3-il)aminopirimidino dariniai kaip kinazės lrrk2 moduliatoriai skirti parkinsono ligos gydymui |
US20140228384A1 (en) * | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
CA2852609C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
CN106349234A (zh) * | 2011-11-29 | 2017-01-25 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
WO2013079496A1 (en) * | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
CN106279202A (zh) * | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
CN106220615A (zh) * | 2012-05-03 | 2016-12-14 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的吡唑氨基嘧啶衍生物 |
JP6189948B2 (ja) | 2012-06-29 | 2017-08-30 | ファイザー・インク | LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン |
WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
WO2014134772A1 (en) * | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
MX2016007810A (es) | 2013-12-17 | 2016-09-07 | Merck Patent Gmbh | Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa. |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
EP3082819B1 (en) | 2013-12-20 | 2020-06-17 | Signal Pharmaceuticals, LLC | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
AU2015210593A1 (en) | 2014-01-29 | 2016-07-07 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
CN105980388B (zh) | 2014-01-29 | 2018-01-16 | 葛兰素史密斯克莱知识产权发展有限公司 | 化合物 |
CA2943979A1 (en) * | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
EP2927221A1 (en) * | 2014-03-31 | 2015-10-07 | Commonwealth Scientific and Industrial Research Organisation | Diamine compounds for phosphorescent diazaborole metal complexes and electroluminescent devices |
GB2538476B (en) * | 2014-05-08 | 2019-03-20 | Tosoh F Tech Inc | 5-(Trifluoromethyl)pyrimidine derivatives and method for producing same |
WO2015176010A1 (en) | 2014-05-15 | 2015-11-19 | The United States Of America, As Represented By The Secretary, Departmentof Health & Human Services | Treatment or prevention of an intestinal disease or disorder |
JP6262079B2 (ja) * | 2014-06-02 | 2018-01-17 | 東ソー・ファインケム株式会社 | 4−(2,2,2−トリフルオロエトキシ)−5−(トリフルオロメチル)ピリミジン誘導体及びその製造方法 |
JP6431294B2 (ja) * | 2014-06-16 | 2018-11-28 | 東ソー・ファインケム株式会社 | 5−(トリフルオロメチル)ピリミジン誘導体及びその製造法 |
EP3206691B1 (en) | 2014-10-14 | 2018-09-19 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
WO2017087905A1 (en) * | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
ES2797301T3 (es) | 2016-03-29 | 2020-12-01 | Merck Patent Gmbh | Derivados de piperidinil-propanona |
CN109071490B (zh) | 2016-04-28 | 2021-04-06 | 默克专利股份公司 | 哌啶基衍生物 |
SI3472153T1 (sl) * | 2016-06-16 | 2022-01-31 | Denali Therapeutics Inc. | Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj |
CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
CN110678182B (zh) | 2017-02-24 | 2022-08-23 | 大邱庆北尖端医疗产业振兴财团 | 含有能够穿透血脑屏障的化合物作为预防或治疗脑癌的有效成分的药物组合物 |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
WO2018217946A1 (en) * | 2017-05-24 | 2018-11-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
CN110799503B (zh) * | 2017-06-30 | 2023-06-27 | 美国安进公司 | 美卡奥美坎替的合成 |
EP3652179A1 (en) * | 2017-07-14 | 2020-05-20 | GlaxoSmithKline Intellectual Property Development Ltd | Inhibitors of leucine rich repeat kinase 2 |
US10683297B2 (en) | 2017-11-19 | 2020-06-16 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
MA51222A (fr) | 2017-11-21 | 2020-10-07 | Denali Therapeutics Inc | Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production |
MX2020006641A (es) * | 2017-12-20 | 2021-01-08 | Denali Therapeutics Inc | Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol. |
WO2019160037A1 (ja) * | 2018-02-14 | 2019-08-22 | 国立大学法人 東京大学 | 酸ハロゲン化物による化合物の製造方法 |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
WO2020243635A1 (en) * | 2019-05-31 | 2020-12-03 | Denali Therapeutics Inc. | Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment |
CN110627810B (zh) * | 2019-06-05 | 2024-05-10 | 中国医学科学院药用植物研究所 | 一种三氟甲基吡唑衍生物的制备方法 |
EP4087574A4 (en) * | 2020-03-06 | 2024-01-17 | National Health Research Institutes | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES |
KR102342803B1 (ko) | 2020-03-23 | 2021-12-24 | 환인제약 주식회사 | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 |
US20240254103A9 (en) | 2020-03-23 | 2024-08-01 | Whan In Pharmaceutical Co., Ltd. | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same |
WO2022084210A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk﹘5抑制劑和彼之用途 |
EP4308115A1 (en) * | 2021-03-17 | 2024-01-24 | Merck Sharp & Dohme LLC | Heteroaroyl amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
CA3213359A1 (en) * | 2021-03-26 | 2022-09-29 | Bettina FRANZ | Alk-5 inhibitors and uses thereof |
WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
WO2023224894A1 (en) * | 2022-05-20 | 2023-11-23 | Merck Sharp & Dohme Llc | Macrocycles as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof |
WO2024097394A1 (en) | 2022-11-03 | 2024-05-10 | Denali Therapeutics Inc. | Solid and co-crystal forms of a pyrimidine triazole compound |
WO2024112746A1 (en) | 2022-11-22 | 2024-05-30 | Denali Therapeutics Inc. | Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound |
CN115819405A (zh) * | 2022-12-20 | 2023-03-21 | 沪渝人工智能研究院 | 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用 |
CN118546132A (zh) * | 2023-02-27 | 2024-08-27 | 科辉智药(深圳)新药研究中心有限公司 | 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用 |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1142817A (zh) | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
EP0723533A1 (en) | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
BRPI9909191B8 (pt) | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
US6458823B1 (en) | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
US6172222B1 (en) | 1998-06-08 | 2001-01-09 | American Home Products Corporation | Diaminopyrazoles |
OA11674A (en) | 1998-11-10 | 2005-01-12 | Janssen Pharmaceutica Nv | HIV Replication inhibiting pyrimidines. |
EP1218369B1 (en) | 1999-08-13 | 2008-07-23 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
OA12029A (en) | 1999-09-24 | 2006-04-28 | Janssen Pharmaceutica Nv | Antiviral compositions. |
US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
WO2001085700A2 (en) | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6638926B2 (en) | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
ES2307667T3 (es) | 2000-12-05 | 2008-12-01 | Vertex Pharmaceuticals Incorporated | Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas. |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
MXPA03005696A (es) | 2000-12-21 | 2003-10-06 | Glaxo Group Ltd | Pirimidinaminas como moduladores de angiogenesis. |
CN100436452C (zh) | 2000-12-21 | 2008-11-26 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡唑化合物 |
JP4316893B2 (ja) | 2001-05-16 | 2009-08-19 | バーテックス ファーマシューティカルズ インコーポレイテッド | Srcおよび他のプロテインキナーゼのインヒビター |
PL367130A1 (en) | 2001-05-29 | 2005-02-21 | Schering Aktiengesellschaft | Cdk inhibiting pyrimidines, production thereof and their use as medicaments |
GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
EP1408978A4 (en) | 2001-06-21 | 2005-07-13 | Ariad Pharma Inc | NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE |
JP4510442B2 (ja) | 2001-06-26 | 2010-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | TNF−α発現のN−ヘテロ環インヒビター |
WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
WO2003040141A1 (en) | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders |
CA2463989C (en) | 2001-10-17 | 2012-01-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof |
WO2003032994A2 (de) | 2001-10-17 | 2003-04-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren |
WO2003055489A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US7288547B2 (en) | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
WO2003076437A1 (de) * | 2002-03-11 | 2003-09-18 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
US7504410B2 (en) | 2002-11-28 | 2009-03-17 | Schering Aktiengesellschaft | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
JP4648324B2 (ja) | 2003-05-21 | 2011-03-09 | バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト | ヨードピラゾリルカルボキシアニリド類 |
EP1651619A1 (en) | 2003-07-15 | 2006-05-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamin analogues as vanilloid receptor ligands |
US7122542B2 (en) * | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
CA2533870A1 (en) | 2003-07-30 | 2005-02-10 | Shudong Wang | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
JP4741491B2 (ja) | 2003-08-07 | 2011-08-03 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 抗増殖剤としての2,4−ピリミジンジアミン化合物および使用 |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005118544A2 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
EP1598343A1 (de) | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
US7601714B2 (en) | 2004-07-08 | 2009-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyrimidine derivatives useful as inhibitors of PKC-theta |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
JP2008511659A (ja) | 2004-09-01 | 2008-04-17 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物の合成 |
TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
DK1814878T3 (da) | 2004-11-24 | 2012-05-07 | Rigel Pharmaceuticals Inc | Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf |
US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
JP5208516B2 (ja) | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
DE102005008310A1 (de) | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
EP1705177A1 (en) | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
CA2607901C (en) | 2005-06-13 | 2016-08-16 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine |
US20060281712A1 (en) | 2005-06-14 | 2006-12-14 | Chi-Feng Yen | Pyrimidine compounds |
US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
WO2007023382A2 (en) | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
WO2007030362A1 (en) | 2005-09-07 | 2007-03-15 | Laboratoires Serono Sa. | Ikk inhibitors for the treatment of endometriosis |
EP1934200A1 (en) * | 2005-09-15 | 2008-06-25 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
DE102005048072A1 (de) | 2005-09-24 | 2007-04-05 | Bayer Cropscience Ag | Thiazole als Fungizide |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
PE20080068A1 (es) | 2006-05-15 | 2008-03-17 | Boehringer Ingelheim Int | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora |
DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
KR20090023698A (ko) | 2006-06-15 | 2009-03-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 2-아닐리노-4-아미노알킬렌아미노피리미딘 |
WO2007149789A2 (en) | 2006-06-22 | 2007-12-27 | Applera Corporation | Conversion of target specific amplification to universal sequencing |
JP2009545598A (ja) | 2006-08-01 | 2009-12-24 | プリーシス・ファーマシューティカルズ・インコーポレイテッド | P38キナーゼ阻害剤 |
DE102006041382A1 (de) | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
US20080194575A1 (en) | 2006-10-04 | 2008-08-14 | Naiara Beraza | Treatment for non-alcoholic-steatohepatitis |
KR20090093965A (ko) | 2006-11-27 | 2009-09-02 | 아레스 트레이딩 에스.에이. | 다발성 골수종의 치료 |
CN103641833A (zh) | 2006-12-08 | 2014-03-19 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
US20100144732A1 (en) | 2006-12-19 | 2010-06-10 | Krueger Elaine B | Pyrimidine kinase inhibitors |
EP1939185A1 (de) | 2006-12-20 | 2008-07-02 | Bayer Schering Pharma Aktiengesellschaft | Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs |
CA2673184A1 (en) | 2006-12-22 | 2008-07-03 | Boehringer Ingelheim International Gmbh | New compounds |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
DE102007010801A1 (de) | 2007-03-02 | 2008-09-04 | Bayer Cropscience Ag | Diaminopyrimidine als Fungizide |
WO2008132502A1 (en) | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
AU2008258508A1 (en) | 2007-06-08 | 2008-12-11 | Bayer Cropscience Ag | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
AU2008275918B2 (en) | 2007-07-17 | 2014-01-30 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as PKC inhibitors |
JP5410432B2 (ja) | 2007-09-28 | 2014-02-05 | サイクラセル リミテッド | プロテインキナーゼ阻害剤としてのピリミジン誘導体 |
ES2372900T3 (es) | 2007-10-09 | 2012-01-27 | Dow Agrosciences Llc | Pirimidinil-aril-hidrazonas insecticidas. |
CN101910152B (zh) | 2007-11-16 | 2014-08-06 | 因塞特公司 | 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺 |
EP2231620A1 (en) | 2007-12-03 | 2010-09-29 | Boehringer Ingelheim International GmbH | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
PT2231636E (pt) | 2007-12-07 | 2012-01-02 | Novartis Ag | Derivados de pirazole e a sua utilização a título de inibidores de quinases dependentes de ciclina |
SI2265607T1 (sl) | 2008-02-15 | 2017-06-30 | Rigel Pharmaceuticals, Inc. | Spojine pirimidin-2-amina in njihova uporaba kot inhibitorji JAK kinaz |
CL2009000600A1 (es) | 2008-03-20 | 2010-05-07 | Bayer Cropscience Ag | Uso de compuestos de diaminopirimidina como agentes fitosanitarios; compuestos de diaminopirimidina; su procedimiento de preparacion; agente que los contiene; procedimiento para la preparacion de dicho agente; y procedimiento para combatir plagas de animales y/u hongos dañinos patogenos de plantas. |
WO2009122180A1 (en) | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
EP2303824B1 (en) | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
PE20100087A1 (es) | 2008-06-25 | 2010-02-08 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR073354A1 (es) | 2008-07-31 | 2010-11-03 | Genentech Inc | Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer. |
EP2325175A4 (en) | 2008-09-01 | 2012-03-21 | Astellas Pharma Inc | 2,4-DIAMINOPYRIMIDINVERBINDUNG |
JP2012501981A (ja) | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 殺菌剤としてのヘテロ環置換アニリノピリミジン類 |
EP2161259A1 (de) | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
EA201100436A1 (ru) | 2008-09-03 | 2011-10-31 | Байер Кропсайенс Аг | Гетероциклически замещенные анилинопиримидины в качестве фунгицидов |
JP2012501983A (ja) | 2008-09-03 | 2012-01-26 | バイエル・クロップサイエンス・アーゲー | 4−アルキル−置換ジアミノピリミジン類 |
US20100144722A1 (en) | 2008-09-03 | 2010-06-10 | Dr. Reddy's Laboratories Ltd. | Novel heterocyclic compounds as gata modulators |
US20100137313A1 (en) | 2008-10-03 | 2010-06-03 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
EP3255047B1 (en) | 2009-01-06 | 2021-06-30 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders |
US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
CA2757188A1 (en) * | 2009-03-30 | 2010-10-07 | Astellas Pharma Inc. | Pyrimidine compound |
EP2419423A1 (en) | 2009-04-14 | 2012-02-22 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
CN102498110A (zh) | 2009-06-10 | 2012-06-13 | 雅培制药有限公司 | 作为激酶抑制剂的2-(lh-吡唑-4-基氨基)-嘧啶 |
EP2440534A2 (en) | 2009-06-10 | 2012-04-18 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
EP2443106A1 (en) | 2009-06-18 | 2012-04-25 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
EP2443095A1 (en) | 2009-06-18 | 2012-04-25 | Cellzome Limited | Sulfonamides and sulfamides as zap-70 inhibitors |
AU2010295690B2 (en) | 2009-09-16 | 2016-07-28 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
JP5752691B2 (ja) | 2009-09-29 | 2015-07-22 | グラクソ グループ リミテッドGlaxo Group Limited | 新規化合物 |
CN102811619B (zh) | 2009-11-13 | 2015-04-22 | 金纳斯克公司 | 激酶抑制剂 |
JP5856073B2 (ja) | 2009-12-29 | 2016-02-09 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Ron結合構築体およびその使用方法 |
US8470820B2 (en) | 2010-01-22 | 2013-06-25 | Hoffman-La Roche Inc. | Nitrogen-containing heteroaryl derivatives |
JP5713367B2 (ja) * | 2010-06-04 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lrrk2モジュレーターとしてのアミノピリミジン誘導体 |
CA2852609C (en) * | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
LT2785711T (lt) * | 2011-11-29 | 2016-10-25 | F.Hoffmann-La Roche Ag | 2-(fenil arba pirid-3-il)aminopirimidino dariniai kaip kinazės lrrk2 moduliatoriai skirti parkinsono ligos gydymui |
CN106349234A (zh) * | 2011-11-29 | 2017-01-25 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
AR089182A1 (es) * | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
WO2013079496A1 (en) * | 2011-11-30 | 2013-06-06 | F. Hoffmann-La Roche Ag | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2 |
-
2011
- 2011-11-09 CA CA3017869A patent/CA3017869C/en active Active
- 2011-11-09 AU AU2011328139A patent/AU2011328139A1/en not_active Abandoned
- 2011-11-09 EP EP11782588.5A patent/EP2638031B9/en active Active
- 2011-11-09 ES ES16180927T patent/ES2746134T3/es active Active
- 2011-11-09 MX MX2013005199A patent/MX2013005199A/es active IP Right Grant
- 2011-11-09 CN CN201180053793.8A patent/CN103313978B/zh active Active
- 2011-11-09 EP EP16180927.2A patent/EP3124483B1/en active Active
- 2011-11-09 HU HUE16180927A patent/HUE046617T2/hu unknown
- 2011-11-09 ES ES11782588.5T patent/ES2653967T3/es active Active
- 2011-11-09 TW TW100140970A patent/TW201302733A/zh unknown
- 2011-11-09 HU HUE11782588A patent/HUE037844T2/hu unknown
- 2011-11-09 BR BR112013011600-5A patent/BR112013011600B1/pt active IP Right Grant
- 2011-11-09 RS RS20171211A patent/RS56583B1/sr unknown
- 2011-11-09 CA CA2812669A patent/CA2812669C/en active Active
- 2011-11-09 PL PL16180927T patent/PL3124483T3/pl unknown
- 2011-11-09 SG SG2013021100A patent/SG189043A1/en unknown
- 2011-11-09 KR KR1020137014605A patent/KR101566091B1/ko active IP Right Grant
- 2011-11-09 PL PL11782588T patent/PL2638031T3/pl unknown
- 2011-11-09 SI SI201131377T patent/SI2638031T1/en unknown
- 2011-11-09 SI SI201131772T patent/SI3124483T1/sl unknown
- 2011-11-09 LT LTEP16180927.2T patent/LT3124483T/lt unknown
- 2011-11-09 DK DK11782588.5T patent/DK2638031T3/en active
- 2011-11-09 US US13/292,668 patent/US8815882B2/en active Active
- 2011-11-09 DK DK16180927.2T patent/DK3124483T3/da active
- 2011-11-09 PT PT117825885T patent/PT2638031T/pt unknown
- 2011-11-09 LT LTEP11782588.5T patent/LT2638031T/lt unknown
- 2011-11-09 NO NO11782588A patent/NO2638031T3/no unknown
- 2011-11-09 EP EP19184916.5A patent/EP3590933B1/en active Active
- 2011-11-09 JP JP2013538172A patent/JP5986094B2/ja active Active
- 2011-11-09 PT PT161809272T patent/PT3124483T/pt unknown
- 2011-11-09 AR ARP110104181A patent/AR083813A1/es not_active Application Discontinuation
- 2011-11-09 RS RS20191033A patent/RS59106B1/sr unknown
- 2011-11-09 WO PCT/EP2011/069696 patent/WO2012062783A1/en active Application Filing
-
2013
- 2013-03-14 IL IL225234A patent/IL225234A0/en unknown
- 2013-05-03 MA MA35869A patent/MA34644B1/fr unknown
- 2013-05-08 EC ECSP13012611 patent/ECSP13012611A/es unknown
-
2014
- 2014-01-16 HK HK14100468.7A patent/HK1187605A1/xx unknown
-
2016
- 2016-08-04 JP JP2016153608A patent/JP6298115B2/ja active Active
-
2017
- 2017-12-27 CY CY20171101349T patent/CY1120073T1/el unknown
- 2017-12-29 HR HRP20172006TT patent/HRP20172006T1/hr unknown
-
2018
- 2018-02-22 JP JP2018029462A patent/JP6524284B2/ja active Active
-
2019
- 2019-10-02 HR HRP20191781TT patent/HRP20191781T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013011600A8 (pt) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
BR112012030820A2 (pt) | "derivados de aminopirimidina como moduladores de lrrk2" | |
BR112014011850A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
BR112014009717A8 (pt) | derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson. | |
BR112014012217A2 (pt) | derivados de 2-fenilaminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson | |
BR112014011219A2 (pt) | derivados de aminopirimidina como moduladores de lrrk2 | |
BR112014027117A8 (pt) | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição | |
BR112014026952A2 (pt) | derivados de aminopirimidina pirazol como moduladores lrrk2 | |
GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
CR20110195A (es) | Compuestos heteroaromáticos espirocíclicos fusionados para el tratamiento de infecciones bacterianas | |
MX2013001614A (es) | Compuestos heterociclico. | |
BR112014013974A8 (pt) | derivados de sulfonamida benzílicos como moduladores de rorc | |
BR112013026807A2 (pt) | derivados de metil amina bicíclicos substituídos como moduladores dos receptores de esfinfgosina-1 fosfato | |
BR112015009395A2 (pt) | processo para preparação de derivados do ácido biliar | |
BR122018070508B8 (pt) | derivados de arilamida triazol-substituída e seu uso | |
ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
PH12015501293B1 (en) | Imidazopyridazine derivatives as gabaa receptor modulators | |
BR112012006387A2 (pt) | aminas de triazol fundidas como moduladores de p2x7 | |
MA32723B1 (fr) | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments | |
BR112012031340A2 (pt) | derivados de cianoquinolina | |
BR112017001334A2 (pt) | compostos de imidazopiridazina, seu uso e composição farmacêutica que os compreende | |
BR112013027395A2 (pt) | inibidores de 17alfa-hidroxilase/c17,20-liase | |
BR112013027982A2 (pt) | derivados de isoindolinona | |
TN2013000034A1 (en) | Heterocyclic compound and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: GENENTECH, INC. (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/11/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |